Not surprising at all. Although I think anyone who says to short it is downright delusional. This stock is not a pump because it has a reputable pipeline of trial drugs that aim to treat Hep C, a big problem nowadays with 160 million people affected. A pump? A short play? Take those words and shove it. This stock hasn't released news, yes, but it is significantly undervalued at 6 bucks a share. CNAT is still up over 40% for the week. In looking at the bigger picture you begin to understand why CNAT is down 15% today. What goes up-- or in this case "rockets skyward"-- must come down to a reasonable level. Do not expect anything, do not trust what people say on the internet. Read the 10-K, make your move.